Epidemiological evidence and laboratory data strongly support a critical role for androgens in the origin and promotion of epithelial ovarian cancer and have led to clinical trials designed to target the AR (reviewed in ref. [19]). The gene discussed is AR; the disease is ovarian carcinoma.